Illinois Cancer Specialists Posted on: 14 Apr 14

Illinois Cancer Specialists (ICS) united in healing with The US Oncology Network announced today that the physicians with Fox Valley Hematology & Oncology (FVHO) will join its oncology and hematology practice to expand and enhance patient services in Chicago and the Northwest suburbs.

This announcement comes just a year and a half after Hinsdale Hematology-Oncology Associates joined ICS further expanding the practice and its cancer care services. The six board-certified physicians of FVHO will unite with the 18 oncologists of ICS to offer state-of-the-art comprehensive cancer care and enhanced services to oncology and hematology patients in ten locations across the Chicago area close to their homes and families.

The physicians and staff here at Fox Valley Hematology & Oncology have been dedicated to bringing the latest innovations and evidence-based medicine to cancer care for more than 25 years said Chilakamarri Yeshwant M.D. F.A.C.P. founder of FVHO. By joining forces with Illinois Cancer Specialists we can collaborate with other like-minded physicians to advance cancer care even further while remaining committed to the compassionate personalized patient care for which we are known throughout our community.

Illinois Cancer Specialists is united in healing with The US Oncology Network one of the nations largest networks of integrated community-based oncology practices dedicated to advancing high-quality evidence-based cancer care. By joining ICS physicians from FVHO will have access to physician-led evidence-based treatment guidelines as well as opportunities to collaborate with an expanded physician community. This includes access to network-wide physician committees and conferences as well as The Oncology Portal where approximately 1000 physicians can share best practices and collaborate on complex cases.

We are thrilled to have the physicians of Fox Valley join our team said David Hakimian M.D. practice president ICS. They bring to ICS five additional location options as well as access to another six physicians specializing in hematology and oncology all aligned around the common goal of helping our patients win their fight against cancer.

Illinois Cancer Specialists provides Chicago area patients with advanced comprehensive compassionate cancer care. The expanded practice employs the latest technologies and drug therapies to ensure patients receive high-quality care for their particular diagnosis in a collaborative compassionate setting. ICS treatment centers feature outpatient treatment including chemotherapy radiation therapy positron emission tomography (PET) computerized tomography (CT) stem cell transplant clinical research laboratory x-ray studies and specialized pharmaceuticals.

Illinois Cancer Specialists now serves the communities in and around the Chicago area with ten locations including Hinsdale Bolingbrook Arlington Heights Chicago Niles Elgin McHenry Woodstock Hoffman Estates and Huntley.

About Illinois Cancer Specialists

Illinois Cancer Specialists (ICS) is dedicated to providing convenient compassionate leading-edge cancer care to patients in Chicago and the surrounding areas. With more than 30 years in practice and over 400 years of combined physician experience ICS is changing the forefront of patient care. Our dedicated and highly-skilled physicians and staff who specialize in caring for patients with cancer and blood disorders provide unparalleled access to the most innovative advanced therapies and latest technologies throughout Chicago and the surrounding areas. With more than 20 board certified physicians ICS offers convenient compassionate care in ten locations including Hinsdale Bolingbrook Arlington Heights Chicago Niles Elgin McHenry Woodstock Hoffman Estates and Huntley. For more information about Illinois Cancer Specialists visit http://www.illinoiscancerspecialists.com.

More:
Press Release

Arthritis in Dogs & Cats Joints, Tendons & Ligaments in Horses

What Results Have Dog Owners Reported? Greater than 80% of dogs with arthritis have improved Quality of Life Here are outcome survey results for Older Dogs Here are outcome survey results for Younger Dogs Here are outcome survey results for Dogs on Pain Medication

What Results Have Horse Owners Reported? Suspensory Ligament Injuries: 76% returned to Full Work - Prior Level Tendon Injuries: 77% returned to Full Work - Prior Level Joint Disease: 57% returned to Full Work - Prior Level

What is the Process? Stem cells are processed from your animals own fat.

What Do Stem Cells Do?

LOCATE A VETERINARIAN

Dogs & Cats >LEARN MORE See how Vet-Stem Cell Therapy can improve the lives of dogs, cats and pet owners.

Horses>LEARN MORE See how Vet-Stem Cell Therapy has helped horses return to performance.

More:
What Can Be Treated with Vet-Stem Cells? - Pet and Horse ...

Photo credit: Steve Sweitzer

Meet Malibu, a white shepherd, who was picture-perfect at six weeks of age when she was adopted by her family. Energetic, with a zest for chasing after and jumping for her toy ball, Boo thrived on being active.

Fast forward nine years. Its 2008 and age has taken its toll. Boo has great difficulty standing up and struggles to walk to her dog bed. She limps painfully and her back arches, bracing from the pain of severe arthritis in her hips.

Boo wasnt responding significantly to traditional anti-inflammatory treatment for her arthritis. Her owners, Steve and Sheila Sweitzer, were worried about her quality of life. But, they discovered there was a new option for Boo: Stem cell regenerative treatment surgery.

This revolutionary treatment for dogs can helpbut pet owners should be financially prepared. The average cost for stem cell treatment for a dog costs approximately $2,500.

Stem cells hold immense promise for medical treatment because they can take on the traits of all kinds of cells and then replicate many times over. But theyre also the subject of fierce controversy because the most versatile cells can only be derived from embryos.

But what if you can utilize stem cells found in your own body? Not only is it possible, its also proven to be effective in animals.

Vet-Stem Regenerative Veterinary Medicine in San Diego, Calif., has spent the past 20 years developing a successful stem cell treatment for animals.

Vet-Stem CEO and founder Robert Harmon says that during their development phase Vet-Stems treated nearly 3,000 horses, many with joint problems. One of those, a race horse named Be A Bono had bone chips and fluid buildup in his knees that threatened to end his prize-winning careerand his life.

After receiving stem cell treatment, Be A Bono returned to the race track and has since earned more than $1.25 million in prize money.

Read the original:
Stem Cell Treatment for Dogs - pet insurance

Worlds First Affordable In-House Stem Cell Procedure Kit

What is stem cell therapy? Stem cells are the bodys repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc.

What are the different types of stem cells? There are two basic types of stem cells; embryonic and somatic (adult). Embryonic stem cells are found in the placenta and embryo. These cells are called totipotent, which means they have the ability to reproduce into any mature cell type. While embryonic stem cells offer the greatest potential in healing, there are obviously moral and ethical concerns in harvesting these cells.

The second type of stem cell is the adult stem cell. These stem cells are called multipotent, which means they can differentiate into closely related cell lines, but they are not capable of creating a complete organ. Adult stem cells are found in the bone marrow, adipose tissue (fat), skin, liver, blood vessels, and neurons. Contrary to embryonic stem cells, there are no moral or ethical concerns in harvesting these cells, activating them, and reintroducing them back to the patient in areas where healing and regeneration is needed.

So why do we take the cells from adipose (fat) tissue? Adult stem cells are highly concentrated in the fat tissue. There are 50 to 1,000 times more stem cells in the fat than the bone marrow. At this concentration, it is no longer necessary to culture the stem cells to acquire the necessary cell numbers to make a healing impact. The procedure to extract fat from the patient is much quicker and less invasive than a spay. The stem cells are contained within a pool of cells in the fat termed the Stromal Vascular Fraction (SVF). The SVF may impart anti-inflammatory effects, add bioactive peptides, and contribute to reformation and architectural organization. These are benefits lost once stem cells are cultured.

So what can we do with the stem cells? Adult stem cells are capable of dividing into many different cell types. With this capability, we can use them as a treatment for joint injuries, ligament and tendon damage, and fractured bones. Research and clinical trials currently support the use of stem cells in these conditions. Ongoing research is targeting other areas of the body for treatment and the preliminary results are very encouraging.

So what makes MediVet Americas technology better? With our patented LED technology and by incorporating Platelet-Rich Plasma (PRP) the same treatment used by many sports professionals, Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs is able to acquire the most living stem cells of any company currently offering this technology. If your beloved pet is going to have to endure the surgical procedure, we want to make sure they are going to get the most out of it! Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs also offers Cryobanking, where you can store extra cells from the procedure for future use.

So how will the procedure work? The day of the procedure, the veterinarian will anesthetize your pet. They will surgically remove a couple tablespoons of fat. This is a quick and simple procedure that is generally easier than performing a spay. They will then process the fat to remove the stem cells. Processing generally takes a couple of hours. After the stem cells have been collected, your pet will generally be sedated and the stem cells will be administered into the affected joints and/or into the bloodstream. It is important that you do not feed your pet the night before the procedure.

When will I see results? We expect you to see results! While we know every animal is different and there are no guarantees, we have seen positive clinical improvement in 95% of the arthritic cases performed nationwide. Some owners have even reported seeing a difference in as little as a week! While quick results are possible, we expect you to begin seeing improvement within the first 90 days following treatment. Really bad arthritis may require multiple injections, so banking your extra cells is always a good idea!

Is this procedure safe? As with any procedure that involves anesthesia, there is always a risk. However, the stem cells are coming from your pet and are being re-administered back to your pet. There is no risk of an allergic reaction. In rare casesthere might be a mild immune reaction in the injected joint that should subside within a day or two.

Read the original post:
Pet Stem Cell Therapy Stem Cells Research

Worlds First Affordable In-House Stem Cell Procedure Kit

What is stem cell therapy? Stem cells are the bodys repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc.

What are the different types of stem cells? There are two basic types of stem cells; embryonic and somatic (adult). Embryonic stem cells are found in the placenta and embryo. These cells are called totipotent, which means they have the ability to reproduce into any mature cell type. While embryonic stem cells offer the greatest potential in healing, there are obviously moral and ethical concerns in harvesting these cells.

The second type of stem cell is the adult stem cell. These stem cells are called multipotent, which means they can differentiate into closely related cell lines, but they are not capable of creating a complete organ. Adult stem cells are found in the bone marrow, adipose tissue (fat), skin, liver, blood vessels, and neurons. Contrary to embryonic stem cells, there are no moral or ethical concerns in harvesting these cells, activating them, and reintroducing them back to the patient in areas where healing and regeneration is needed.

So why do we take the cells from adipose (fat) tissue? Adult stem cells are highly concentrated in the fat tissue. There are 50 to 1,000 times more stem cells in the fat than the bone marrow. At this concentration, it is no longer necessary to culture the stem cells to acquire the necessary cell numbers to make a healing impact. The procedure to extract fat from the patient is much quicker and less invasive than a spay. The stem cells are contained within a pool of cells in the fat termed the Stromal Vascular Fraction (SVF). The SVF may impart anti-inflammatory effects, add bioactive peptides, and contribute to reformation and architectural organization. These are benefits lost once stem cells are cultured.

So what can we do with the stem cells? Adult stem cells are capable of dividing into many different cell types. With this capability, we can use them as a treatment for joint injuries, ligament and tendon damage, and fractured bones. Research and clinical trials currently support the use of stem cells in these conditions. Ongoing research is targeting other areas of the body for treatment and the preliminary results are very encouraging.

So what makes MediVet Americas technology better? With our patented LED technology and by incorporating Platelet-Rich Plasma (PRP) the same treatment used by many sports professionals, Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs is able to acquire the most living stem cells of any company currently offering this technology. If your beloved pet is going to have to endure the surgical procedure, we want to make sure they are going to get the most out of it! Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs also offers Cryobanking, where you can store extra cells from the procedure for future use.

So how will the procedure work? The day of the procedure, the veterinarian will anesthetize your pet. They will surgically remove a couple tablespoons of fat. This is a quick and simple procedure that is generally easier than performing a spay. They will then process the fat to remove the stem cells. Processing generally takes a couple of hours. After the stem cells have been collected, your pet will generally be sedated and the stem cells will be administered into the affected joints and/or into the bloodstream. It is important that you do not feed your pet the night before the procedure.

When will I see results? We expect you to see results! While we know every animal is different and there are no guarantees, we have seen positive clinical improvement in 95% of the arthritic cases performed nationwide. Some owners have even reported seeing a difference in as little as a week! While quick results are possible, we expect you to begin seeing improvement within the first 90 days following treatment. Really bad arthritis may require multiple injections, so banking your extra cells is always a good idea!

Is this procedure safe? As with any procedure that involves anesthesia, there is always a risk. However, the stem cells are coming from your pet and are being re-administered back to your pet. There is no risk of an allergic reaction. In rare casesthere might be a mild immune reaction in the injected joint that should subside within a day or two.

Read more from the original source:
Pet Stem Cell Therapy | StemCell Therapy MD

Dr. Nazareth #39;s Experience with Veterinary Stem Cells
Watch veterinarian Dr. Darrell Nazareth discuss the advantages of animal stem cell treatment provided by StemLogix. The cutting-edge technology developed by Stemlogix helps treat injured or aging animals in the quickest and most affordable way possible. Dr. Nazareth explains the key differences between StemLogix and other veterinary applications of animal stem cell therapy, such as the expedited service StemLogix administers. Dr. Nazareth illustrates the efficiency of the StemLogix system comparing the cost and time using an off-site laboratory, as opposed to the in-house delivery of viable pet stem cells in just one procedure. To learn more about pet stem cell therapy and its many applications including pet arthritis, visit: stemlogix.com StemLogix LLC Telephone: 954.260.7118 1640 Sweetgum Terrace Weston, Florida 33327 Email: info@stemlogix.comFrom:StemLogixLLCViews:106 0ratingsTime:05:49More inPets Animals

More:
Dr. Nazareth's Experience with Veterinary Stem Cells - Video

StemLogix: Revolutionary Animal Stem Cell Therapy
StemLogix, developer of the pioneering in-clinic animal stem cell therapy solutions, exceeds the standard for delivery and application of veterinary regenerative medicine. Watch veterinarians Dr. Dennis Vrooman, Dr. David Laurence, and Dr. Sean Back of Beach Pet Hospital discuss how StemLogix #39;s revolutionary new method of stem cell treatments for suffering animals and pets. The veterinarians of Beach Pet Hospital reveal and demonstrate the process and application of veterinary stem cell treatments for dogs, cats, and horses, highlighting the efficiency and cost effectiveness of utilizing in-house laboratory techniques. StemLogix trains veterinarians how to create viable doses of pet stem cells on location and supplies all necessary equipment for successful stem cell extraction. From harvesting, cultivating, then reintroducing animal stem cells occurs within one veterinary procedure, saving time, money, and preventing undue stress for both patient and owner. Therapeutic veterinary stem cell can be used in a great number of applications such as arthritis, joint problems or disease, ligament damage, and elbow or hip dysplasia in animals and pets. StemLogix offers a safe and natural option to relieving pain and mobility issues within pets as opposed to medication and supplements. To learn more about animal and pet stem cell therapy and veterinary regenerative medicine, visit: stemlogix.com StemLogix LLC Telephone: 954.260.7118 1640 Sweetgum Terrace Weston, Florida 33327 Email ...From:StemLogixLLCViews:497 0ratingsTime:04:43More inPets Animals

Continued here:
StemLogix: Revolutionary Animal Stem Cell Therapy - Video

MADISON, Wis., Oct. 3, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Jamey Weichert, Ph.D., Lance Hall, M.D., Anne M. Traynor, M.D., Glenn Liu, M.D. and their colleagues is being made by Dr. Weichert at the Imaging in 2020 Conference taking place September 30 to October 4, 2012 in Jackson Hole, Wyoming. This presentation describes the mechanistic foundation for Novelos' diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged uptake of Novelos' PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types. Dr. Weichert is Associate Professor of Radiology, Dr. Hall is Assistant Professor of Radiology, Dr. Traynor is Associate Professor of Medicine and Dr. Liu is Associate Professor of Medicine, all in the School of Medicine and Public Health at the University of Wisconsin, Madison and all are members of the UW Carbone Cancer Center. Dr. Weichert is also the Chief Scientific Officer of Novelos and the founder of Novelos' technology.

"LIGHT, HOT and GLOW2 were designed to exploit a common feature of most, if not all cancer cells including cancer stem cells that results in their selective uptake and retention in a wide range of malignant tumors compared with normal tissues," said Dr. Weichert. "By incorporating a unique functional property in each, we have generated an array of potential products that could, singly and in combinations, significantly improve the detection and treatment of cancer in multiple ways."

Slides of the oral presentation are available at http://www.novelos.com/technology-ip/posters-publications/

In the presentation, titled Molecular Diapeutics: Phospholipid Ether Analogs as Broad-Spectrum Cancer and Cancer Stem Cell Detection and Treatment, Dr. Weichert presents data showing that LIGHT, HOT and GLOW2 all share a common cancer-targeted core chemical structure. Each attaches a unique moiety to this delivery vehicle LIGHT a PET imaging agent (iodine-124), HOT a radiotherapeutic agent (iodine-131) and GLOW2 an optical imaging agent (near-infrared tracer). Results described with LIGHT demonstrate broad-spectrum tumor PET imaging in dozens of animal tumor models, and recent human findings in ongoing Phase 1-2 clinical trials show selective uptake and retention by primary tumors and metastases in advanced non-small cell lung and brain cancer patients. HOT results shown include single-dose efficacy in a wide range of animal tumor models as well as selective uptake and retention in cancerous tumors in clinical trials to date. The presentation highlights the potential diapeutic application of LIGHT and HOT, based on their chemical identity, to provide individualized treatment to cancer patients. For example, LIGHT serves as an ideal biomarker to potentially identify patients most likely to benefit from therapy with HOT. Dr. Weichert's talk also describes how selective uptake of GLOW2 could provide better definition of tumor margins in real time during cancer surgery, enabling more complete and selective removal of malignant tissue and potentially improving patients' prognosis. Data illustrating the potential use of GLOW2 for non-invasive detection of tumors is also being shown.

"We are pleased to share the science behind Novelos' cancer-targeted diapeutic platform with the scientific community attending this prestigious conference," said Harry Palmin, President and CEO of Novelos. "As we have recently reported, we continue to make good clinical progress with LIGHT and HOT across multiple human trials while advancing GLOW2 towards human trials."

About Novelos Therapeutics, Inc.

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

INVESTOR CONTACTS

J. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

Read the original post:
Novelos Therapeutics and Academic Collaborators Present Diapeutic Technology Platform at Imaging in 2020 Conference

MADISON, Wisc., Oct. 2, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present a corporate update at the 11th Annual BIO Investor Forum on Wednesday, October 10, 2012. Mr. Palmin is scheduled to present at 2:30pm PT in the Sea Cliff room. The conference will take place October 9-10 at the Palace Hotel in San Francisco.

A live webcast of the Novelos presentation may be accessed via http://www.novelos.com

The webcast will be archived for 90 days following the presentation.

The BIO Investor Forum is an international investor conference featuring leading private and emerging public biotech companies. Information about the conference is available at http://www.bio.org/events/conferences/11th-annual-bio-investor-forum

About Novelos Therapeutics, Inc.We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

INVESTOR CONTACTSJ. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Read the original:
Novelos Therapeutics to Present at 11th Annual Bio Investor Forum on October 10

Animal Cell Therapies, Inc., a veterinary regenerative therapies company, is announcing the commitment of $1.5 million to develop a proprietary line of canine orthopedic products called PROTECT.

SAN DIEGO, CA (PRWEB) September 28, 2012

"This type of financial commitment demonstrates that we are dedicated to propelling innovation and providing solutions for veterinarians, pets and pet owners, said Dr. Kathy Petrucci, Chief Medical Officer of Animal Cell Therapies.

The dedicated funds will allow Animal Cell Therapies, in partnership with leading researchers, to fully develop the PROTECT Cell Therapy product portfolio. The portfolio will include a proprietary cell processing procedure, patented materials, precise protocols and an all-inclusive operating system.

We believe R&D capital allocated to strategic partnerships is a necessary step towards commercialization. said Adam Irving, Chief Executive Officer of Animal Cell Therapies.

About Animal Cell Therapies

Founded in January 2009 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Companys California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit http://www.actcells.com.

Preston Munsch Animal Cell Therapies, Inc. (858) 678-8843 Email Information

More here:
Animal Cell Therapies Announces $1.5 million Developmental Work in Canine Orthopedic Product Line